Understanding PIQRAY

PIQRAY® (alpelisib) tablets + fulvestrant

Watch the PIQRAY TV Commercial to learn more about PIQRAY.


Want to know more?

Find out about the results of PIQRAY + fulvestrant.

PIQRAY + fulvestrant is for postmenopausal women and men, who:



Test positive for a mutation, or abnormality, in a gene called PIK3CA.
Plus Minus


Have HR+, HER2- advanced or metastatic breast cancer.


Have progressed on or after hormone therapy.


It is not known if PIQRAY is safe and effective in children.

What is PIQRAY?

PIQRAY is the first and only treatment option specifically for patients with PIK3CA mutations in HR+, HER2- metastatic breast cancer (mBC). It's a biomarker-driven treatment approach, which means that your doctor will test your breast cancer for an abnormal PIK3CA gene to make sure that PIQRAY is right for you. Learn more about PIK3CA mutation testing.




PIK3CA mutations affect about 40% of people with HR+, HER2- mBC.







PIK3CA mutations have been linked to cancer growth.







PIQRAY works by targeting the effects of the PIK3CA mutation.*

*PIQRAY affects cancer cells, but can also affect healthy cells. Although PIQRAY has been studied in people with HR+, HER2- mBC, how PIQRAY works has only been demonstrated in laboratory studies.

If you have a PIK3CA mutation and progressed on or after hormone therapy, PIQRAY may be right for you.

You didn't choose metastatic breast cancer, but you still have choices to make. Learn more about PIQRAY and how knowing your options can help you and your doctor to pick the right treatment for your specific type of mBC.